Published on October 9, 2009 at 9:17 AM
MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors. These funds help provide additional runway to finance our ongoing European Sepsis Trial and the CE Mark application process."
Additional information regarding the warrant exercise can be viewed in the Company's 8-K filed with the SEC on October 9, 2009, which is available at http://www.sec.gov.
SOURCE: MedaSorb Technologies Corporation